Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Palo Alto Networks Inc (PANW) Price & Performance

Inovio Pharmaceuticals IncTrade
Palo Alto Networks IncTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Palo Alto Networks Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Palo Alto Networks Inc trades at $387 (market cap $312.80B). The key difference: Palo Alto Networks Inc is far larger — about 3982.2× Inovio Pharmaceuticals Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

INOPANW
Market Cap
$78.55M$312.80B
Sector
HealthTechnology
52-Week High
$2.87$385.04
52-Week Low
$0.66$141.67
Enterprise Value
$49.56M$311.76B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Palo Alto Networks Inc

Palo Alto Networks (PANW) trades at $386.64, up 0.42% today, nearing its 52-week high with strong bullish technical signals. Recent earnings beats, including Q1 2026 EPS of $0.85 versus $0.793 expected, and robust revenue growth to $9.22B in 2025 highlight fundamental strength. Positive sentiment is driven by AI cybersecurity demand, as noted in recent news, though valuation ratios like P/E of 333.74 remain elevated.

Outlook is optimistic due to cybersecurity tailwinds and AI innovation, but risks include high valuation, integration costs from acquisitions, and regulatory scrutiny, such as China's cybersecurity review. Analyst consensus is strongly bullish with a $344.94 price target, suggesting potential downside from current levels amid growth execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Palo Alto Networks Inc

Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.

Read more on PANW